Agios Pharmaceuticals said it will stop developing tebapivat, its next-generation oral pyruvate kinase activator, for sickle cell disease after Phase 2 results failed to demonstrate sufficient differentiation to justify continued development. Agios characterized the study outcome as not meeting the level of “differentiation required” for further work. The decision adds to a run of sickle cell setbacks across the sector and pressures Agios’ competitive positioning in an area where Novo Nordisk’s approach has shown late-stage momentum. For Agios, the tebapivat write-down also increases attention on Pyrukynd (mitapivat), while investors watch how the company allocates resources. Analysts highlighted that with tebapivat discontinued, Novo’s position strengthens as etavopivat advances. The episode underscores the high bar for differentiation in enzyme-activator strategies within sickle cell.